Effect of human recombinant LZ-TRAIL on the growth of established human plasmacytoma xenografts in nu/xid/bg mice.

Nu/xid/bg mice were injected subcutaneously with human S6B45 MM cells. On establishment of palpable xenografts, the mice (8/cohort) received either PBS or recombinant human LZ-TRAIL (500 μg intraperitoneally daily for 14 days). TRAIL was well tolerated by the mice and suppressed the growth of the established human plasmacytomas, in contrast to the significant increase in the tumor burden generated in PBS-treated control mice.